There is evidence that some of the circadian photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), project directly to the amygdala, an area of the brain implicated in PTSD. Thus, a self-administered morning light treatment at home (shifts clock earlier and stimulates ipRGCs) may be a potentially efficacious adjunctive strategy for reducing PTSD symptoms. This study will test a 4 week daily 1 hour morning light treatment (active vs placebo) in individuals with PTSD. Outcome measures include measures of PTSD and depression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
15
The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
Rush University Medical Center
Chicago, Illinois, United States
Change in PTSD Checklist for DSM-5 (PCL-5) Scores Over 4 Weeks of Treatment
The PTSD Checklist for DSM-5 (PCL-5) is the gold standard measure of PTSD symptom severity. Range: 0-80. Higher scores indicate worse outcomes. We will assess change in PCL-5 scores over 4 weeks of treatment \[Week 2 through Week 6 of the study\].
Time frame: Week 2 and Week 6
Change in Patient Health Questionnaire - 9 (PHQ-9) Scores Over 4 Weeks of Treatment
The Patient Health Questionnaire - 9 (PHQ-9) is the gold standard measure of depression symptom severity. Range: 0-27. Higher scores indicate worse outcomes. We will assess change in PHQ-9 scores over 4 weeks of treatment \[Week 2 through Week 6 of the study\].
Time frame: Week 2 and Week 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.